T
TScan Therapeutics
An experienced group of scientists, development specialists, and other leaders driving a cutting edge platform
About TScan Therapeutics
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer patients. The company's primary focus is on creating therapies for hematologic malignancies, specifically targeting residual leukemia cells to prevent relapse following hematopoietic stem cell transplantation. TScan's lead candidates, TSC-100 and TSC-101, are currently in development for these purposes.
Operating in the biopharmaceutical sector, TScan serves patients with cancer, particularly those undergoing stem cell transplants. The company employs a business model centered around research and development (R&D) of innovative therapies, with revenue generation primarily through funding, grants, and potential future sales of approved therapies. TScan's market includes healthcare providers, hospitals, and specialized cancer treatment centers.
The company makes money by advancing its pipeline of TCR-T therapies through clinical trials, securing partnerships, and eventually commercializing its products upon regulatory approval.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Dec 2024 | $30M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Dec 2024 | $53M | — | Silicon Valley Bank | ↗ |
Growth signals
Latest recorded traffic for TScan Therapeutics is 9K monthly website visits, up 55.2% over the last three months. TScan Therapeutics's team declined 12.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TScan Therapeutics in the Waltham ecosystem
The TScan Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Longwood Fund
Novartis Venture Fund
Bessemer Venture Partners
Pitango Venture Capital
6 Dimensions Capital
Series B and later4 investors entered at this stage
BlackRock
RA Capital Management
K2 HealthVentures
Silicon Valley Bank
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TScan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TScan Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










